Diary Prequel Package — page 424

This is a complete distortion. The trial was stopped because patients died and the FDA sent a threatening letter to the company. Questions on this will undoubtedly come up as we launch the ZMapp trial. These same individuals accused us in print of being unethical for doing RCTs. Lu - I need to know what I (or Tony) can say publicly. For the first time in a 35 year career at the NIH I am taking my gloves off. Tony - I intend to severe any and all collaborations we have with the Wellcome Trust over what I consider to be completely unethical behavior and lack of integrity. Peggy - if I had not worked with you when you were a special assistant in Tony's off ice there is no chance I would see such a note to the FDA Commissioner. I apologize in advance. Somewhere in HHS we need to move from political correctness and deference to our colleagues in other agencies to doing the right thing and trying our best to identify effective countermeasures for Ebola virus disease. It is possible my judgement is being skewed by spending too much time in West Africa. In fact, however, it I think it has been honed. I think we need a blunt meeting with the Secretary and Leadership of FDA, CDC and NIH to put the cards on the table face up. Cliff On Feb 3, 2015, at 7:27 PM, Doepel, Laurie (NIH/NIAID) [E] <LDOEPEL@niaid.nih.gov> wrote: Low infection rate halts Ebola vaccine trials in Liberia By Afp Published: 14:17 EST, 3 February 2015 I Updated: 14:17 EST, 3 February 2015 Britain's Wellcome Trust said that clinical trials it was funding for a new Ebola vaccine in Liberia were halted on Tuesday due to a fall in new cases. "The current position is that there is no realistic prospect of the trial enrolling sufficient patients to be able to reach a conclusion about the